Adaptin Bio (APTN) Cash from Financing Activities (2023 - 2026)

Adaptin Bio's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $438433.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 90.51% year-over-year to $438433.0; the TTM figure through Mar 2026 stood at $1.0 million (down 80.39% YoY), while the FY2025 annual figure was $5.2 million, up 666.71% from the prior year.
• Cash from Financing Activities came in at $438433.0 for Q1 2026 at Adaptin Bio, down from $582961.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $4.6 million in Q1 2025 to a low of -$193876.0 in Q4 2024.
• A 4-year average of $797296.9 and a median of $330487.5 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 432.28% in 2024 and jumped 5033.36% in 2025, its largest moves.
• Adaptin Bio's Cash from Financing Activities stood at $58347.0 in 2023, then tumbled by 432.28% to -$193876.0 in 2024, then surged by 400.69% to $582961.0 in 2025, then retreated by 24.79% to $438433.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $438433.0, $582961.0, and $4.6 million for Q1 2026, Q4 2025, and Q1 2025 respectively.

Peer Comparison